Quantitative liquid chromatographic-tandem mass spectrometric determination of orlistat in plasma with a quadrupole ion trap.
This report evaluates the use of a quadrupolar ion trap for quantitation in a bioanalytical laboratory. The evaluation was accomplished with the cross-validation of an LC-MS-MS quantitative method previously validated on a triple quadrupole mass spectrometer. The method was a multi-level determination of the anti-obesity drug, orlistat, in human plasma. The method has been refined previously on a triple quadrupole instrument to provide rapid sample throughput with robust reproducibility at sub-nanogram detection limits. Optimization of the method on the ion trap required improved chromatographic separation of orlistat from interfering plasma matrix components coextracted during the initial liquid-liquid extraction of plasma samples. The ion trap produces full-scan collision-induced dissociation mass spectra containing characteristic orlistat fragment ions that are useful for quantitation. Data collection on the ion trap required a precursor ion isolation width of 3.0 Da and optimal quantitative results were obtained when three fragment ions were monitored with a 1.8 Da window for each ion. Although a direct cross-validation between the ion trap and the tandem triple quadrupole mass spectrometer was not possible, quantitative results for orlistat comparable to those obtained from the triple quadrupole instrument were achieved by the ion trap with the modified method. The limit of quantitation for orlistat in plasma on the ion trap was 0.3 ng ml(-1) with a linear dynamic range of 0.3 to 10 ng ml(-1). Precision and accuracy varied from 4 to 15% over the quantitation range. The overall results provide an example of the utility of an ion trap in bioanalytical work.
Wieboldt
R
R
Analytical Toxicology, Cornell University, New York State College of Veterinary Medicine, Ithaca 14850, USA.
Campbell
D A
DA
Henion
J
J
D002853:Chromatography, Liquid / Q000379:methods*; D004791:Enzyme Inhibitors / Q000097:blood*; D005069:Evaluation Studies as Topic; D006801:Humans; D007477:Ions; D007783:Lactones / Q000097:blood*; D008049:Lipase / Q000037:antagonists & inhibitors; D013058:Mass Spectrometry / Q000379:methods*; D000077403:Orlistat
D004791:Enzyme Inhibitors; D007477:Ions; D007783:Lactones; D000077403:Orlistat; D008049:Lipase